Xianqiang Song
Senior Director - Structural Biology Structure Therapeutics
Xianqiang Song is Senior Director of Structural Biology at Structure Therapeutics, where he leads an industrial-scale Structural Biology platform dedicated to GPCR drug targets. His team delivers high-resolution cryo-EM structures at atomic detail, enabling rapid, rational small molecule design. By integrating structural biology with computational chemistry, the team accelerates Structure Therapeutics’ metabolic disease pipeline, driving the transition from early hits to optimized leads. At the summit, he will share insights on harnessing GPCR structural biology to drive small molecule discovery in metabolic disease therapeutics
Seminars
Exploring the unique hurdles of designing drugs for RNA, PROTACs, and beyond. Panellists will discuss structural and physicochemical challenges, computational and biophysical tool limitations, permeability and delivery barriers, and the need for novel screening and optimization strategies to unlock these emerging therapeutic modalities.
Discussion Points:
- What structural and physicochemical features make RNA, macrocycles, and PROTACs especially challenging compared to small molecules?
- How can computational chemistry, structural biology, and biophysics be adapted to better interrogate these modalities?
- What strategies are most promising for improving permeability, stability, and delivery of large or complex molecules?
- How can we build robust optimization workflows to balance potency, selectivity, and drug-like properties across different modalities?
- Dissecting GLP-1 conformational states with small molecule ligands to map downstream pharmacological effects
- Accelerating insights through advanced computational and data-driven approaches
- Translating structural and computational findings into actionable guidance for medicinal chemistry efforts
